PMID- 22437221
OWN - NLM
STAT- MEDLINE
DCOM- 20120727
LR  - 20221207
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 124
IP  - 2
DP  - 2012 Mar
TI  - Tolerability of concomitant use of selective serotonin reuptake inhibitors or 
      serotonin-norepinephrine reuptake inhibitors and oxymorphone extended release.
PG  - 114-22
LID - 10.3810/pgm.2012.03.2542 [doi]
AB  - BACKGROUND: Opioids and antidepressants are frequently prescribed for chronic low 
      back pain (cLBP). This post hoc analysis was conducted to assess the tolerability 
      of oxymorphone extended release (ER) for cLBP in patients taking selective 
      serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake 
      inhibitors (SNRIs) compared with patients not taking SSRIs/SNRIs. METHODS: 
      Patients in 2 clinical trials (NCT00225797, November 22, 2004 to July 18, 2005; 
      NCT00226421, October 13, 2004 to August 19, 2005) aged >/= 18 years with moderate 
      to severe cLBP were titrated to a stabilized dose of oxymorphone ER during an 
      open-label titration phase and then randomized to treatment with this dose or 
      placebo every 12 hours for 12 weeks. In a post hoc analysis, adverse events (AEs) 
      were compared between patients taking versus not taking SSRIs/SNRIs. Treatment 
      efficacy was assessed as change from baseline in average daily pain intensity on 
      a 100-mm visual analog scale. RESULTS: Of 575 patients enrolled, 45 of 89 (50.6%) 
      taking SSRIs/SNRIs and 303 of 486 (62.3%) not taking SSRIs/SNRIs successfully 
      titrated to oxymorphone ER. The frequency of any AE did not differ significantly 
      between the 2 subpopulations. During the titration phase, serious AEs occurred 
      more frequently in patients taking SSRIs/SNRIs (3/89; 3.4%) compared with those 
      not taking SSRIs/SNRIs (4/486; 0.8%; P = 0.04); however, during the double-blind 
      treatment phase, there was no significant difference in the frequency of serious 
      AEs in patients treated with oxymorphone ER taking (1/29; 3.4%) versus those not 
      taking (3/146; 2.0%) SSRIs/SNRIs. Visual analog scale scores were similar in 
      patients taking versus those not taking SSRIs/SNRIs throughout the study. 
      CONCLUSION: The concomitant use of oxymorphone ER with SSRIs or SNRIs was well 
      tolerated in patients with cLBP.
FAU - Peniston, John H
AU  - Peniston JH
AD  - Primary Care Physician, Feasterville Family Health Care Center, Jamison, PA, USA. 
      Jhpdo@aol.com
FAU - Hu, Xiaojun
AU  - Hu X
FAU - Potts, Susan L
AU  - Potts SL
FAU - Wieman, Matthew S
AU  - Wieman MS
FAU - Turk, Dennis C
AU  - Turk DC
LA  - eng
SI  - ClinicalTrials.gov/NCT00225797
SI  - ClinicalTrials.gov/NCT00226421
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 9VXA968E0C (Oxymorphone)
SB  - IM
MH  - Adolescent
MH  - Adrenergic Uptake Inhibitors/*adverse effects/therapeutic use
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analgesics, Opioid/*adverse effects/therapeutic use
MH  - Anxiety/complications/drug therapy
MH  - Chronic Pain/complications/*drug therapy
MH  - Delayed-Action Preparations
MH  - Depression/complications/drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Low Back Pain/complications/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Oxymorphone/*adverse effects/therapeutic use
MH  - Pain Measurement
MH  - Selective Serotonin Reuptake Inhibitors/*adverse effects/therapeutic use
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2012/03/23 06:00
MHDA- 2012/07/28 06:00
CRDT- 2012/03/23 06:00
PHST- 2012/03/23 06:00 [entrez]
PHST- 2012/03/23 06:00 [pubmed]
PHST- 2012/07/28 06:00 [medline]
AID - 10.3810/pgm.2012.03.2542 [doi]
PST - ppublish
SO  - Postgrad Med. 2012 Mar;124(2):114-22. doi: 10.3810/pgm.2012.03.2542.